Strategies for More Complex Bioanalysis

Sponsored by: Gyros Protein Technologies

Focused on:

  • Bioanalysis
  • Immunoassays
  • Assay Development
  • Reagent Screening

Date: 23 March


Time: 2PM London/10AM New York

Using Automated Nanoliter-Scale Immunoassays for Improved Performance and Efficiency

Therapeutic constructs such as bi-specifics, antibody drug conjugates and non-traditional therapeutics such as immunotherapies require more complex bioanalysis in measuring surrogate biomarker endpoints and pharmacokinetics (PK).

These complex analyses further complicate development. Automation and miniaturization using Gyrolab platforms redefine performance and efficiency in the development of these constructs, such as streamlined method development and reagent screening.

Gyrolab’s affinity flow-through format minimizes matrix effects to improve performance and eliminates incubations for more rapid time to results at a higher throughput. This webinar will present case studies featuring reagent screening and method development for a variety of different biotherapeutics – traditional and non-conventional constructs.

Presented by

Karolina Österlund,

Director – Field Service and Application Support, EU and Asia Gyros Protein Technologies

Christophe Henry, Ph.D.,

Laboratory Head / Translational Medicine

Key Learning Objectives

  • Gyrolab is a reliable immunoassay platform providing higher throughput for assay development and biomarker clinical assessment in human plasma
  • Rapid reagent screening of nanobodies; over 100 combinations in parallel
  • Reagent screening using peptides using Gyrolab to improve a tedious, low-throughput method


  • Scientist
  • Group Leaders
  • Director
  • Senior Scientist
  • Executive Director
  • Vice President
  • Associate Director
  • Bioanalytical Scientist
  • Principal Scientist
  • Research Investigator
  • Research Scientist
  • Senior Director
  • Bioanalytical Research Associate